文献速递呼吸道感染

基于随机试验数据预测社区获得性肺炎辅助糖皮质激素治疗的获益人群

Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials.
PubMed 文献 · Lancet Respir Med · 2025-01-29

该个体患者数据荟萃分析纳入8项随机对照试验共3224例住院社区获得性肺炎(CAP)患者,评估辅助糖皮质激素对30天死亡率的效果异质性。

核心结论

  • 辅助糖皮质激素总体显著降低住院CAP患者30天死亡率,但效果异质性显著,仅高基线CRP患者获益明显。

研究设计与样本

  • 个体患者数据荟萃分析,纳入2024年7月1日前发表的8项随机对照试验,共3224例住院CAP患者,比较辅助糖皮质激素与安慰剂,主要终点为30天全因死亡率,按意向性治疗原则分析。

主要发现

  • 较不严重CAP(PSI I-III级,n=229)与严重CAP(PSI IV-V级,n=1126)间未发现显著治疗效果异质性。

关键数值与推荐

  • 基于CRP的效应模型:CRP≤204 mg/L预测无获益,CRP>204 mg/L预测有获益。
  • PSI分级I-III级与IV-V级间未显示显著效果异质性。

临床怎么用

  • 对住院CAP患者,可依据基线CRP水平(>204 mg/L)筛选可能从辅助糖皮质激素治疗中显著获益的人群。
  • 使用糖皮质激素时需监测高血糖和再入院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite several randomised controlled trials (RCTs) on the use of adjuvant treatment with corticosteroids in patients with community-acquired pneumonia (CAP), the effect of this intervention on mortality remains controversial. We aimed to evaluate heterogeneity of treatment effect (HTE) of adjuvant treatment with corticosteroids on 30-day mortality in patients with CAP. METHODS: In this individual patient data meta-analysis, we included RCTs published before July 1, 2024, comparing adjuvant treatment with corticosteroids versus placebo in patients hospitalised with CAP. The primary endpoint was 30-day all-cause mortality, collected across all trials, and analyses followed the intention-to-treat principle. We analysed HTE using risk and effect modelling. For risk modelling, patients were classified as having less severe or severe CAP based on the pneumonia severity index (PSI), comparing PSI class I-III versus class IV-V. For effect modelling, we trained a corticosteroid-effect model on six trials and externally validated it using data from two trials, received after model preregistration. This model classified patients into two groups: no predicted benefit and predicted benefit from adjuvant treatment with corticosteroids. The literature search was registered on PROSPERO, CRD42022380746. FINDINGS: We included eight RCTs with 3224 patients. Across all eight trials, 246 (7·6%) patients died within 30 days (106 [6·6%] of 1618 in the corticosteroid group vs 140 [8·7%] of 1606 in the placebo group; odds ratio [OR] 0·72 [95% CI 0·56-0·94], p=0·017). The corticosteroid-effect model, which selected C-reactive protein (CRP), showed significant HTE during external validation in the two most recent trials. In these trials, 154 (11·4%) of 1355 patients died within 30 days (88 [13·1%] of 671 in the placebo group vs 66 [9·6%] of 684 in the corticosteroid group; OR 0·71 [95% CI 0·50-0·99], p=0·044). Among patients predicted to have no benefit (CRP ≤204 mg/L, n=725), no significant effect was observed (OR 0·98 [95% CI 0·63-1·50]), whereas for those with predicted benefit (CRP >204 mg/L, n=630), 39 (13·0%) of 301 patients died in the placebo group compared with 20 (6·1%) of 329 in the corticosteroid group (0·43 [0·25-0·76], pinteraction=0·026). No significant HTE was found between less severe CAP (PSI class I-III, n=229) and severe CAP (PSI class IV-V, n=1126). Corticosteroid therapy significantly increased hyperglycaemia risk (44 [12·8%] of 344 in the placebo group vs 84 [24·8%] of 339 in the corticosteroid group; OR 2·50 [95% CI 1·63-3·83], p<0·0001) and hospital re-admission risk (30 [3·7%] of 814 in the placebo group vs 57 [7·0%] of 819 in the corticosteroid group; 1·95 [1·24-3·07], p=0·0038). INTERPRETATION: Overall, adjuvant therapy with corticosteroids significantly reduces 30-day mortality in patients hospitalised with CAP. The treatment effect varied significantly among subgroups based on CRP concentrations, with a substantial mortality reduction observed only in patients with high baseline CRP. FUNDING: None.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Smit, Van Der Zee, Stoof, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med. 2025. PMID: 39892408. doi:10.1016/S2213-2600(24)00405-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。